These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 11404068

  • 1. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
    Biedenbach DJ, Jones RN, Pfaller MA, Sentry Participants Group (Americas and Europe).
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):245-50. PubMed ID: 11404068
    [Abstract] [Full Text] [Related]

  • 2. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
    Jones RN, Biedenbach DJ.
    Diagn Microbiol Infect Dis; 2003 Apr; 45(4):273-8. PubMed ID: 12729999
    [Abstract] [Full Text] [Related]

  • 3. Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.
    Jones RN, Biedenbach DJ, Erwin ME, Beach ML, Pfaller MA.
    J Clin Microbiol; 1999 Jun; 37(6):1999-2002. PubMed ID: 10325362
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of fluoroquinolones against common respiratory pathogens.
    Aydemir S, Tunger A, Cilli F.
    West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812
    [Abstract] [Full Text] [Related]

  • 5. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999).
    Gales A, Sader H, Jones RN, SENTRY Participants Group (Latin America).
    Antimicrob Agents Chemother; 2001 May; 45(5):1463-6. PubMed ID: 11302811
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study.
    Jones ME, Staples AM, Critchley I, Thornsberry C, Heinze P, Engler HD, Sahm DF.
    Diagn Microbiol Infect Dis; 2000 Jul; 37(3):203-11. PubMed ID: 10904194
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN, Fritsche TR, Sader HS, Stilwell MG.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756.
    Bell JM, Turnidge JD, Jones RN, SENTRY Regional Participants Group.
    Int J Antimicrob Agents; 2002 Feb; 19(2):125-32. PubMed ID: 11850165
    [Abstract] [Full Text] [Related]

  • 12. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001.
    Jones ME, Blosser-Middleton RS, Critchley IA, Karlowsky JA, Thornsberry C, Sahm DF.
    Clin Microbiol Infect; 2003 Jul; 9(7):590-9. PubMed ID: 12925097
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
    Dorai-John T, Thomson CJ, Amyes SG.
    J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America).
    Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2000 Apr; 36(4):255-9. PubMed ID: 10764968
    [Abstract] [Full Text] [Related]

  • 17. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
    Bogdanovich T, Clark C, Ednie L, Lin G, Smith K, Shapiro S, Appelbaum PC.
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2050-7. PubMed ID: 16723565
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Brueggemann AB, Kugler KC, Doern GV.
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1594-7. PubMed ID: 9210692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.